ArticleVirology2008
Immunogenicity and protection efficacy of subunit-based smallpox vaccines using variola major antigens.
Article in Virology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 40 citations in OpenAlex.
- The first key for the Priority Pathogens: Protective immunogens in development of vaccines and medications.Biosafety and health · 2026Review
- An mRNA vaccine against monkeypox virus inhibits infection by co-activation of humoral and cellular immune responses.Nature communications · 2025Article
- Monoclonal Antibodies in Light of Mpox Outbreak: Current Research, Therapeutic Targets, and Animal Models.Antibodies (Basel, Switzerland) · 2025Review
- Post-Vaccination Delivery of CpG ODNs Enhances the Th2-Associated Protective Immunity of the Smallpox DNA Vaccine.Molecular biotechnology · 2024Article
- Rational design of a 'two-in-one' immunogen DAM drives potent immune response against mpox virus.Nature immunology · 2024Article
- Review
- Design of inhibitors of thymidylate kinase fromJournal of biomolecular structure & dynamics · 2019Article
- Defending against smallpox: a focus on vaccines.Expert review of vaccines · 2016Review
- Structural and Functional Characterization of Anti-A33 Antibodies Reveal a Potent Cross-Species Orthopoxviruses Neutralizer.PLoS pathogens · 2015Article
- Preventing the return of smallpox: molecular modeling studies on thymidylate kinase from Variola virus.Journal of biomolecular structure & dynamics · 2014Article
- DNA immunization.Current protocols in microbiology · 2013Article
- Active vaccination with vaccinia virus A33 protects mice against lethal vaccinia and ectromelia viruses but not against cowpoxvirus; elucidation of the specific adaptive immune response.Virology journal · 2013Article
- Article
- Humoral immunity to smallpox vaccines and monkeypox virus challenge: proteomic assessment and clinical correlations.Journal of virology · 2013Article
- A vaccinia virus renaissance: new vaccine and immunotherapeutic uses after smallpox eradication.Human vaccines & immunotherapeutics · 2012Review
- Polyclonal antibody cocktails generated using DNA vaccine technology protect in murine models of orthopoxvirus disease.Virology journal · 2011Article
- Establishment of the black-tailed prairie dog (Cynomys ludovicianus) as a novel animal model for comparing smallpox vaccines administered preexposure in both high- and low-dose monkeypox virus challenges.Journal of virology · 2011Article
- The strategic use of novel smallpox vaccines in the post-eradication world.Expert review of vaccines · 2011Review
- Genomic expression libraries for the identification of cross-reactive orthopoxvirus antigens.PloS one · 2011Article
- The identification of HLA class II-restricted T cell epitopes to vaccinia virus membrane proteins.Virology · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
The viral strain responsible for smallpox infection is variola major (VARV). As a result of the successful eradication of smallpox with the vaccinia virus (VACV), the general population is no longer required to receive a smallpox vaccine, and will have no protection against smallpox. This lack of immunity is a concern due to the potential for use of smallpox as a biological weapon. Considerable progress has been made in the development of subunit-based smallpox vaccines resulting from the identification of VACV protective antigens. It also offers the possibility of using antigens from VARV to formulate the next generation subunit-based smallpox vaccines. Here, we show that codon-optimized DNA vaccines expressing three VARV antigens (A30, B7 and F8) and their recombinant protein counterparts elicited high-titer, cross-reactive, VACV neutralizing antibody responses in mice. Vaccinated mice were protected from intraperitoneal and intranasal challenges with VACV. These results suggest the feasibility of a subunit smallpox vaccine based on VARV antigen sequences to induce immunity against poxvirus infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.